171 related articles for article (PubMed ID: 23723314)
1. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
[TBL] [Abstract][Full Text] [Related]
2. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management.
Akaza H; Carroll P; Cooperberg MR; Hinotsu S
Jpn J Clin Oncol; 2012 Mar; 42(3):226-36. PubMed ID: 22217576
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
Cooperberg MR; Hinotsu S; Namiki M; Ito K; Broering J; Carroll PR; Akaza H
J Clin Oncol; 2009 Sep; 27(26):4306-13. PubMed ID: 19667269
[TBL] [Abstract][Full Text] [Related]
4. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.
Tanaka N; Fujimoto K; Hirayama A; Yoneda T; Yoshida K; Hirao Y
Jpn J Clin Oncol; 2010 Jun; 40(6):588-92. PubMed ID: 20299498
[TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
6. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
9. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE.
Akaza H; Hinotsu S; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Hirao Y; Murai M; Yamanaka H; Namiki M
J Urol; 2006 Dec; 176(6 Pt 2):S47-9. PubMed ID: 17084166
[TBL] [Abstract][Full Text] [Related]
10. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation as a strategy for prostate cancer chemoprevention.
Aquilina JW; Lipsky JJ; Bostwick DG
J Natl Cancer Inst; 1997 May; 89(10):689-96. PubMed ID: 9168183
[No Abstract] [Full Text] [Related]
12. Prostate cancer, Incidence, management and outcomes.
Small EJ
Drugs Aging; 1998 Jul; 13(1):71-81. PubMed ID: 9679210
[TBL] [Abstract][Full Text] [Related]
13. [Surgical and medical treatment for localized prostate cancer].
Kawai K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
[TBL] [Abstract][Full Text] [Related]
14. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
[TBL] [Abstract][Full Text] [Related]
15. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
16. The prostate cancer conundrum.
Albertsen PC
J Natl Cancer Inst; 2003 Jul; 95(13):930-1. PubMed ID: 12837821
[No Abstract] [Full Text] [Related]
17. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
Hinotsu S; Akaza H; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Namiki M; Hirao Y; Murai M; Yamanaka H;
Jpn J Clin Oncol; 2007 Oct; 37(10):775-81. PubMed ID: 17965423
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention for prostatic intraepithelial neoplasia.
Nelson PS; Gleason TP; Brawer MK
Eur Urol; 1996; 30(2):269-78. PubMed ID: 8875211
[TBL] [Abstract][Full Text] [Related]
19. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
20. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]